Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 7/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL865572 | 1.00 | YAP1 (0.57) | YAP1GPR119ALDH1A1LMNAMAPK1 | |
| SCHEMBL864987 | 0.92 | YAP1 (0.57) | YAP1GPR119ALDH1A1LMNAMAPK1 | |
| SCHEMBL864986 | 0.92 | YAP1 (0.57) | YAP1GPR119ALDH1A1LMNAMAPK1 | |
| SCHEMBL865749 | 0.88 | YAP1 (0.45) | YAP1GPR119ALDH1A1LMNAMAPK1 | |
| SCHEMBL865748 | 0.88 | YAP1 (0.45) | YAP1GPR119ALDH1A1LMNAMAPK1 | |
| SCHEMBL865750 | 0.88 | YAP1 (0.45) | YAP1GPR119ALDH1A1LMNAMAPK1 | |
| SCHEMBL864889 | 0.85 | YAP1 (0.44) | YAP1ALDH1A1LMNAMAPK1 | |
| SCHEMBL864888 | 0.85 | YAP1 (0.44) | YAP1ALDH1A1LMNAMAPK1 | |
| SCHEMBL864890 | 0.85 | YAP1 (0.44) | YAP1ALDH1A1LMNAMAPK1 | |
| SCHEMBL3498974 | 0.85 | YAP1 (0.53) | YAP1ALDH1A1LMNABCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| EP-2406247-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103333-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | YAP1 3922/4885GPR119 1/4885ALDH1A1 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.